21:50 , Jun 5, 2019 |  BC Extra  |  Financial News

Oncolytic virus play OncoMyx raises $25M series A

Arizona State University spinout OncoMyx raised $25 million in a series A round to develop its oncolytic virus programs in solid cancers. Boehringer Ingelheim Venture Fund, Delos Capital and Xeraya Capital co-led the tranched financing....
13:05 , Apr 25, 2019 |  BC Extra  |  Preclinical News

Engineered Cas9 derivatives avoid T cell reactivity

Arizona State University researchers have engineered Cas9 to avoid pre-existing immunity against the bacterial protein, a safety concern for in vivo CRISPR-Cas9 gene editing. Samira Kiani, an ASU assistant professor who co-led the study, told...
02:03 , Feb 23, 2019 |  BioCentury  |  Product Development

Benchmarks for NASH

Benchmarking clinical value in NASH will require more than the topline data reported this week by Intercept Pharmaceuticals Inc. The readout gained Ocaliva obeticholic acid the title of first NASH therapy to meet in Phase...
16:57 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Intercept's NASH therapy heads for submissions after meeting Phase III endpoint

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) intends to submit regulatory applications next half for obeticholic acid (OCA) after new data showed the compound met one of two primary endpoints in the Phase III REGENERATE trial to treat...
17:52 , Feb 19, 2019 |  BC Extra  |  Clinical News

Intercept's NASH therapy heads for submissions after meeting Phase III endpoint

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) intends to submit regulatory applications next half for obeticholic acid (OCA) after new data showed the compound met one of two primary endpoints in the Phase III REGENERATE study to treat...
16:01 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to enter the adaptive Phase II/III GBM AGILE trial, which has been designed to more rapidly...
13:00 , Nov 14, 2018 |  BC Extra  |  Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to enter the adaptive Phase II/III GBM AGILE trial, which has been designed to more rapidly...
19:20 , Feb 21, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles DNA-based nucleolin-targeting nanoparticles could be used to deliver therapies for cancer. The nanoparticles consist of DNA tubes with an inner surface conjugated to therapeutic cargos and an outer surface linked to aptamers that...
20:02 , Aug 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Necroptosis strikes again

Adding to the list of necroptosis-related pathologies, a group from Arizona State University has shown the cell death pathway is activated in Alzheimer’s disease. The data, published last month in Nature Neuroscience , identify potential...
23:33 , Apr 14, 2017 |  BioCentury  |  Product Development

New endpoints in NASH

Data on mid-stage NASH candidates to be presented at the European Association for the Study of the Liver’s International Liver Congress this month won’t enable solid comparisons with each other or with more advanced programs....